Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • dschika
    Member
    • Mar 2010
    • 56

    Replace N's in R2 read, if I know the sequence

    Hi,

    I have a library which was constructed using a restriction enzyme (ApeKI). A paired-end 100 bp Illumina sequencing was performed.
    The R1 (first read of a pair) reads consisted of a barcode and sequence and were fine. No barcode was added to R2 reads. Therefore, R2 reads should always start with the same sequence (C A/T GC). In most cases that is true, but unfortunately about 15 % of the reads have a 'N' at position 1, and 30 % of the reads have 'N' at position 4. In the filtering steps I usually remove sequences with at least one 'N', resulting in a loss of more than 30 % of the reads at the moment.

    The other reads look good and can be mapped against the reference without problem, i.e. there was no general problem with the sequencing (else I would not expect the remaining reads to match the reference).

    Since I haven't seen a publication yet where they described something like that, my question is:

    Can I replace the N's at position 1 and 4 since I know what the sequence should be, before performing quality filtering? Do you see any problems with that approach?

    Some programs need the restriction enzyme cutsite for analysis, that is why I do not want to just trim the first 4 nucleotides...
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #2
    Rather than changing primary data (which reviewers may not look upon kindly down the road) you should consider adding phiX to this sample and re-run (if you do not have enough data). Low nucleotide diversity is never good for illumina runs and one of the manifestations is the problem (N's) you experienced.

    Alternatively give up on the 15% reads that have this problem and use the remainder (if you have enough good data).

    Comment

    • dschika
      Member
      • Mar 2010
      • 56

      #3
      Thanks for your comment, GenoMax. I also think that reviewers would not be too happy with anyone changing raw data. And I also do not like the idea so much.

      Unfortunately, re-running is not a possibility. The run was spiked with PhiX, but only 1%.

      To circumvent the low diversity problems, R1 reads started with barcodes of different length and composition, to ensure high diversity. As far as I know, low diversity at the start of the R2 reads should not be too problematic, since "calibration" is performed at the start of R1 reads. The parameters of R1 reads are then also used in R2 read sequencing. But I am not too sure about that.

      In my first post, I was not precise enough: until now, I trimmed the first 5 positions of all reads, performed further quality checks (more than 90% of nucleotides have to have qualities higher than 20), and then mapped the reads. I could not see any difference between those reads with or without 'N' in the first 5 positions except of those 'N's.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        Today, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Today, 11:10 AM
      0 responses
      7 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-13-2026, 10:26 AM
      0 responses
      29 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-09-2026, 10:04 AM
      0 responses
      38 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-08-2026, 10:08 AM
      0 responses
      25 views
      0 reactions
      Last Post SEQadmin2  
      Working...